CTRI/2020/09/028131已完成未知
A Randomized, Double Blind, Placebo Controlled Study toEvaluate the Efficacy and Safety of Cordyceps Capsules (Food Supplement) as an Add-On Therapy in Patients with Mild to Moderate COVID 19 Infection
Ambrosia Food Farm Co0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients with mild to Moderate Category COVID-19 patients
- •2.Male or female patients ââ?°Â¥18 years of age.
- •3.Patients with or without co-morbidities (stable diabetes or/and hypertension with medications).
- •4.Voluntary willingness to give written informed consent prior to participation in trial.
- •5.Male patients who is willing to follow contraceptive measures .
- •6.Female should be of non-childbearing potential, either surgically sterile or postmenopausal.
- •7.Female of childbearing potential should agree to use effective contraceptive measures
- •8.Willingness and ability to comply with trial and follow-up procedures.
排除标准
- •1.Patients who refuse to give consent for participation.
- •2.Patients with severe COVID-19 infection
- •3.Patient with asymptomatic infection.
- •4.Patients who are allergic to Cordyceps Capsules.
- •5.Patients already enrolled in another intervention trial.
- •6.Patients who receive immunomodulant therapy like Tocilizumab or convalescent plasma or high-dose pulse steroid therapy.
- •7.Autoimmune diseases such as multiple sclerosis (MS), systemic lupus erythematosus (SLE) rheumatoid arthritis (RA) other conditions.
- •8.Patients with any bleeding disorder e.g. hemophilia and von Willebrand disease.
- •9.Patients in whom the surgeries are planned during the study.
- •10.Pregnant or breastfeeding.
- •11.Concurrent condition that in the investigatorââ?¬•s opinion would jeopardize compliance with the protocol.
- •12.Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
研究者
相似试验
尚未招募
3 期
Effectiveness of Bacillus Coagulans in improving appetite among patients admitted in hospitalCTRI/2018/11/016404Hindu Mission Hospital
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Patients With Mild to Moderate HypertensioMen and women, 35-70 years old with mild to moderate Hypertension as classified by the British Hypertension Society (BHS) Guidelines - BHS-IV based on the following crietia of sitting blood pressure measured by spygomanography for patienst without diabetes or renal dysfunction:Grade 1 (mild): Systolic BP 140-159 mmHG and Diastolic BP of 90-99 mmHgGrade 2 (moderate): Systolic BP 160-179 mmHg and Diastolic BP 100-109 mmHgMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionMedDRA version: 9.1Level: PTClassification code 10020772Term: HypertensionMedDRA version: 9.1Level: PTClassification code 10042957Term: Systolic hypertensionMedDRA version: 9.1Level: PTClassification code 10012758Term: Diastolic hypertensionEUCTR2008-001001-41-GBProtherics Medicines Development Ltd, a BTG plc company
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) - 20060198low or intermediate-1 risk MDSMedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2007-007258-75-ITAmgen Inc.240
已完成
不适用
Effectiveness and safety of a herbal composition to improve Aging Male SymptomsCTRI/2019/02/017506aila Neutraceuticals Pvt Ltd
招募中
3 期
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Aerosolized JH509 in Hospitalized Adult Patients with Mild to Moderate COVID 19COVID-19 infections diseaseJPRN-jRCT2051200159Shoji Hashimoto385